Marble Harbor Investment Counsel LLC Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

Marble Harbor Investment Counsel LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,174 shares of the medical device company’s stock after selling 222 shares during the quarter. DexCom accounts for about 2.0% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 14th largest position. Marble Harbor Investment Counsel LLC’s holdings in DexCom were worth $16,687,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Capital World Investors lifted its stake in shares of DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares in the last quarter. Norges Bank purchased a new position in shares of DexCom in the fourth quarter valued at about $540,178,000. Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the period. Finally, Sands Capital Management LLC grew its position in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 1.0 %

Shares of DXCM opened at $69.51 on Monday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company’s fifty day simple moving average is $82.36 and its 200-day simple moving average is $111.23. The company has a market cap of $27.64 billion, a P/E ratio of 44.85, a P/E/G ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the business earned $0.34 earnings per share. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on DXCM shares. UBS Group dropped their price target on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. BTIG Research dropped their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Oppenheimer decreased their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Robert W. Baird increased their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Finally, Morgan Stanley reduced their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold 2,483 shares of company stock valued at $201,708 in the last quarter. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.